Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 EUR | -2.05% | -7.05% | -9.49% |
04-10 | Transgene: presents vaccine results at AACR | CF |
03-28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Sales 2024 * | 39.2M 42.55M 3.34B | Sales 2025 * | 49.2M 53.4M 4.19B | Capitalization | 125M 136M 10.68B |
---|---|---|---|---|---|
Net income 2024 * | -14M -15.19M -1.19B | Net income 2025 * | -21M -22.79M -1.79B | EV / Sales 2024 * | 3.71 x |
Net Debt 2024 * | 20.2M 21.92M 1.72B | Net Debt 2025 * | 42.1M 45.69M 3.59B | EV / Sales 2025 * | 3.4 x |
P/E ratio 2024 * |
-8.27
x | P/E ratio 2025 * |
-5.64
x | Employees | 141 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.69% |
Latest transcript on Transgene
1 day | -2.05% | ||
1 week | -7.05% | ||
1 month | +1.64% | ||
3 months | +18.32% | ||
6 months | -14.48% | ||
Current year | -9.49% |
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 30/03/22 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 31/03/16 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16/03/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 18/06/13 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 31/12/90 |
Director/Board Member | 63 | 06/12/04 |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 1.24 | -2.05% | 54,648 |
30/05/24 | 1.266 | +0.32% | 8,580 |
29/05/24 | 1.262 | +0.32% | 16,392 |
28/05/24 | 1.258 | -1.41% | 34,591 |
27/05/24 | 1.276 | -4.35% | 56,949 |
Real-time Euronext Paris, May 31, 2024 at 04:29 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.49% | 136M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- TNG Stock